Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

Moderna Inc., profitability ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Return on Sales
Gross profit margin 70.62% 85.19% 96.03%
Operating profit margin 51.10% 75.22% -381.82%
Net profit margin 45.36% 69.04% -373.77%
Return on Investment
Return on equity (ROE) 43.73% 86.26% -29.17% -43.75% -25.14%
Return on assets (ROA) 32.34% 49.46% -10.18% -32.34% -19.61%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Moderna Inc. gross profit margin ratio deteriorated from 2020 to 2021 and from 2021 to 2022.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Moderna Inc. operating profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Moderna Inc. net profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Moderna Inc. ROE improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.
ROA A profitability ratio calculated as net income divided by total assets. Moderna Inc. ROA improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.

Gross Profit Margin

Moderna Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Gross profit 13,019 15,058 192
Product sales 18,435 17,675 200
Profitability Ratio
Gross profit margin1 70.62% 85.19% 96.03%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 70.00% 68.96% 66.41% 77.64%
Amgen Inc. 74.17% 73.44% 74.59% 80.38%
Bristol-Myers Squibb Co. 78.04% 78.57% 72.31% 69.10%
Eli Lilly & Co. 76.77% 74.18% 77.66% 78.85%
Gilead Sciences Inc. 79.03% 75.56% 81.23% 78.86%
Johnson & Johnson 67.26% 68.16% 65.58% 66.42%
Merck & Co. Inc. 70.63% 72.02% 67.74% 69.87%
Pfizer Inc. 65.77% 62.08% 79.26% 80.25%
Regeneron Pharmaceuticals Inc. 87.18% 84.83% 86.82% 90.05%
Thermo Fisher Scientific Inc. 42.24% 50.08% 49.67% 44.35%
Vertex Pharmaceuticals Inc. 87.90% 88.06% 88.14% 86.84%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Product sales
= 100 × 13,019 ÷ 18,435 = 70.62%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Moderna Inc. gross profit margin ratio deteriorated from 2020 to 2021 and from 2021 to 2022.

Operating Profit Margin

Moderna Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Income (loss) from operations 9,420 13,296 (763) (546) (413)
Product sales 18,435 17,675 200
Profitability Ratio
Operating profit margin1 51.10% 75.22% -381.82%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 31.21% 31.89% 24.81% 39.03%
Amgen Inc. 38.57% 31.44% 37.70% 43.57%
Bristol-Myers Squibb Co. 17.96% 15.91% -21.60% 22.62%
Eli Lilly & Co. 24.97% 22.45% 24.69% 22.29%
Gilead Sciences Inc. 27.17% 36.72% 16.72% 19.38%
Johnson & Johnson 24.63% 24.95% 23.60% 24.15%
Merck & Co. Inc. 30.27% 25.74% 16.47% 24.77%
Pfizer Inc. 34.83% 23.91% 19.47% 25.46%
Regeneron Pharmaceuticals Inc. 38.93% 55.67% 42.09% 28.10%
Thermo Fisher Scientific Inc. 18.69% 25.57% 24.19% 17.99%
Vertex Pharmaceuticals Inc. 48.23% 36.73% 46.03% 28.77%
Operating Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.54% 26.95% 18.70% 26.27%
Operating Profit Margin, Industry
Health Care 13.29% 13.19% 10.52% 12.41%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Operating profit margin = 100 × Income (loss) from operations ÷ Product sales
= 100 × 9,420 ÷ 18,435 = 51.10%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Moderna Inc. operating profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.

Net Profit Margin

Moderna Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) 8,362 12,202 (747) (514) (385)
Product sales 18,435 17,675 200
Profitability Ratio
Net profit margin1 45.36% 69.04% -373.77%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 20.39% 20.54% 10.08% 23.69%
Amgen Inc. 26.42% 24.25% 29.97% 35.32%
Bristol-Myers Squibb Co. 13.71% 15.08% -21.20% 13.15%
Eli Lilly & Co. 21.88% 19.71% 25.24% 37.27%
Gilead Sciences Inc. 17.02% 23.05% 0.51% 24.35%
Johnson & Johnson 18.90% 22.26% 17.82% 18.42%
Merck & Co. Inc. 24.49% 26.79% 14.72% 21.01%
Pfizer Inc. 31.27% 27.04% 22.95% 31.45%
Regeneron Pharmaceuticals Inc. 35.64% 50.25% 41.35% 26.91%
Thermo Fisher Scientific Inc. 15.47% 19.70% 19.79% 14.47%
Vertex Pharmaceuticals Inc. 37.20% 30.92% 43.70% 28.27%
Net Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.57% 23.52% 13.96% 23.55%
Net Profit Margin, Industry
Health Care 10.32% 10.91% 7.86% 10.19%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net profit margin = 100 × Net income (loss) ÷ Product sales
= 100 × 8,362 ÷ 18,435 = 45.36%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Moderna Inc. net profit margin ratio improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.

Return on Equity (ROE)

Moderna Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) 8,362 12,202 (747) (514) (385)
Stockholders’ equity 19,123 14,145 2,561 1,175 1,530
Profitability Ratio
ROE1 43.73% 86.26% -29.17% -43.75% -25.14%
Benchmarks
ROE, Competitors2
AbbVie Inc. 68.60% 74.91% 35.30%
Amgen Inc. 178.97% 87.96% 77.20% 81.07%
Bristol-Myers Squibb Co. 20.37% 19.46% -23.84% 6.66%
Eli Lilly & Co. 58.64% 62.16% 109.79% 319.09%
Gilead Sciences Inc. 21.62% 29.55% 0.68% 23.91%
Johnson & Johnson 23.36% 28.20% 23.25% 25.42%
Merck & Co. Inc. 31.57% 34.17% 27.91% 37.99%
Pfizer Inc. 32.79% 28.47% 15.21% 25.77%
Regeneron Pharmaceuticals Inc. 19.14% 43.03% 31.86% 19.08%
Thermo Fisher Scientific Inc. 15.80% 18.94% 18.47% 12.45%
Vertex Pharmaceuticals Inc. 23.88% 23.19% 31.22% 19.34%
ROE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 29.77% 31.77% 18.32% 29.64%
ROE, Industry
Health Care 22.38% 22.87% 16.20% 21.01%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROE = 100 × Net income (loss) ÷ Stockholders’ equity
= 100 × 8,362 ÷ 19,123 = 43.73%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Moderna Inc. ROE improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.

Return on Assets (ROA)

Moderna Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) 8,362 12,202 (747) (514) (385)
Total assets 25,858 24,669 7,337 1,589 1,962
Profitability Ratio
ROA1 32.34% 49.46% -10.18% -32.34% -19.61%
Benchmarks
ROA, Competitors2
AbbVie Inc. 8.53% 7.88% 3.07% 8.84%
Amgen Inc. 10.06% 9.63% 11.54% 13.13%
Bristol-Myers Squibb Co. 6.53% 6.40% -7.61% 2.65%
Eli Lilly & Co. 12.62% 11.44% 13.28% 21.17%
Gilead Sciences Inc. 7.27% 9.16% 0.18% 8.74%
Johnson & Johnson 9.57% 11.47% 8.41% 9.59%
Merck & Co. Inc. 13.30% 12.35% 7.72% 11.66%
Pfizer Inc. 15.91% 12.11% 6.23% 9.72%
Regeneron Pharmaceuticals Inc. 14.85% 31.75% 20.47% 14.29%
Thermo Fisher Scientific Inc. 7.15% 8.12% 9.23% 6.33%
Vertex Pharmaceuticals Inc. 18.30% 17.44% 23.07% 14.15%
ROA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 10.84% 10.64% 5.51% 9.31%
ROA, Industry
Health Care 8.39% 8.25% 5.52% 7.21%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROA = 100 × Net income (loss) ÷ Total assets
= 100 × 8,362 ÷ 25,858 = 32.34%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Moderna Inc. ROA improved from 2020 to 2021 but then slightly deteriorated from 2021 to 2022.